Clinical trial
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate…
NCT00313313 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00313313 |
|---|---|
| Title | A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas |
| Official title | A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Glyburide in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Glyburide Alone |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes |
| Intervention type | Drug |
| Interventions | Saxagliptin, Glyburide, Placebo, Metformin |
| Enrollment | 768 |
| Start date | Apr 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2008 |
| First posted | Apr 12, 2006 |
| Last update posted | May 4, 2015 |
| Countries | Argentina, Brazil, Hong Kong, Israel, Mexico, Peru, Philippines, Puerto Rico, Singapore, South Africa, South Korea, Taiwan and 1 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: